FLT4 and neoplasm: Overall, our findings offer new insights into the contribution of VEGFR3/FLT4/CD310 inhibition to restoring a pro-inflammatory tumor myeloid compartment and suggest M-LECP cells as candidate fruquintinib targets to overcome immunosuppression in tumors.